2024
Association of Baseline Hepatitis B Virus DNA and On-Treatment Risk of Cirrhosis and Hepatocellular Carcinoma
Yang Z, Cheung R, Jou J, Lim J, Lim Y, Wong R. Association of Baseline Hepatitis B Virus DNA and On-Treatment Risk of Cirrhosis and Hepatocellular Carcinoma. Gastroenterology Research 2024, 17: 109-115. PMID: 38993547, PMCID: PMC11236339, DOI: 10.14740/gr1735.Peer-Reviewed Original ResearchBaseline HBV DNARisk of hepatocellular carcinomaChronic hepatitis BRisk of cirrhosisNon-cirrhotic chronic hepatitis BHepatitis B virus DNAHBV DNAHepatocellular carcinomaHepatitis B virusCHB patientsPropensity score weightingAntiviral therapyAssociated with higher risk of hepatocellular carcinomaHigh risk of hepatocellular carcinomaNon-cirrhotic CHB patientsCohort of CHB patientsLevels of hepatitis B virusContinuous antiviral therapyHigh HBV DNANon-Asian cohortModerate levelsAssociated with higher riskScore weightingB virus DNACox proportional hazards models
2023
Hepatitis B care cascade among people with HIV/HBV coinfection in the North American AIDS Cohort Collaboration on Research and Design, 2012–2016
Kim J, Newcomb C, Carbonari D, Torgersen J, Althoff K, Kitahata M, Klein M, Moore R, Reddy K, Silverberg M, Mayor A, Horberg M, Cachay E, Lim J, Gill M, Chew K, Sterling T, Hull M, Seaberg E, Kirk G, Coburn S, Lang R, McGinnis K, Gebo K, Napravnik S, Kim H, Re V, Research and Design of IeDEA F. Hepatitis B care cascade among people with HIV/HBV coinfection in the North American AIDS Cohort Collaboration on Research and Design, 2012–2016. PLOS ONE 2023, 18: e0290889. PMID: 37656704, PMCID: PMC10473492, DOI: 10.1371/journal.pone.0290889.Peer-Reviewed Original ResearchConceptsNorth American AIDS Cohort CollaborationUndetectable HBV DNAHBV coinfectionHBV DNACare cascadeCohort CollaborationViral suppressionHIV/HBV coinfectionTenofovir-based antiretroviral therapyHIV/HBVAntiretroviral therapy regimenCross-sectional studyDelivery of careHBV therapyHBV treatmentHBV viremiaAntiretroviral therapyHBV infectionHIV infectionTherapy regimenChronic infectionClinical cohortCoinfectionTherapyInfection
2018
An expert consensus for the management of chronic hepatitis B in Asian Americans
Tong MJ, Pan CQ, Han S, Lu D, Raman S, Hu K, Lim JK, Hann HW, Min AD. An expert consensus for the management of chronic hepatitis B in Asian Americans. Alimentary Pharmacology & Therapeutics 2018, 47: 1181-1200. PMID: 29479728, PMCID: PMC5900913, DOI: 10.1111/apt.14577.Peer-Reviewed Original ResearchConceptsChronic hepatitis BAnti-viral therapyHepatocellular carcinomaHepatitis BHBV DNAPregnant womenBasal core promoter mutationsNegative chronic hepatitis BHepatitis B virus infectionAsian American physiciansLiver related deathManagement of HBVDetectable HBV DNAHBeAg-negative patientsHBsAg-positive patientsHBV DNA levelsNormal ALT levelsB virus infectionCore promoter mutationsHBsAg carrier rateLife-long surveillanceContrast CT scanAbdominal ultrasound examinationAlpha-fetoprotein testingAsian American patients
2015
Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study
Ahn J, Lee HM, Lim JK, Pan CQ, Nguyen MH, Kim W, Mannalithara A, Trinh H, Chu D, Tran T, Min A, Do S, Te H, Reddy KR, Lok AS. Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study. Alimentary Pharmacology & Therapeutics 2015, 43: 134-144. PMID: 26510638, PMCID: PMC4926997, DOI: 10.1111/apt.13440.Peer-Reviewed Original ResearchConceptsALT normalisationAdverse eventsHBV DNAHBeAg(-) patientsHBV patientsTreatment-naïve chronic hepatitis B patientsChronic hepatitis B patientsFive-year cumulative probabilityHBsAg loss/seroconversionLog 10 IU/Hepatitis B virus infectionEffectiveness of entecavirMedian HBV DNAUndetectable HBV DNAHepatitis B patientsB virus infectionAbnormal ALTEntecavir treatmentETV treatmentHBeAg lossHBsAg lossHepatic decompensationB patientsCohort studyMedian duration